Form 4: MAIA Biotechnology Director Steven Chaouki Acquires Shares and Warrants

Director Steven M. Chaouki reports purchasing 34,641 shares of MAIA Biotechnology at $1.17 and warrants exercisable at $1.30.

Summary

• On March 14, 2024, Steven M. Chaouki, a director of MAIA Biotechnology, Inc., acquired 34,641 shares of common stock at a price of $1.17 per share.
• Following this transaction, Chaouki directly owns 88,891 shares of MAIA Biotechnology.
• Chaouki also acquired warrants to purchase 34,641 shares of common stock with an exercise price of $1.30.
• The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024.
• The warrants are exercisable beginning on September 14, 2024, and expire on September 14, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the scale of the purchase is relatively small.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
• The acquisition of warrants suggests a longer-term commitment to the company's success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Stakeholder Impact

• The purchase could increase investor confidence in MAIA Biotechnology.
• The purchase has a limited impact on employees, customers, suppliers, and creditors.

Key Dates